7th Eurasian Hematology Oncology Summit

 

7th Eurasian Hematology Oncology Summit
Avatar

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, and Combining Targeted Agents in Relapse/Refractory

By 7th Eurasian Hematology Oncology Summit FEATURING Charles A. Schiffer
By 7th Eurasian Hematology Oncology Summit FEATURING Charles A. Schiffer
695 views
July 24, 2020
Comments 1
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
Lymphoma
14:50

How I Treat Follicular Lymphoma in 2020: Rituximab vs. WW Strategy, …

7th Eurasian Hematology Oncology Summit

G. Gaidano

62 views
19:51

How I Treat DLBCL in 2020: Can Radiotherapy Be Omitted in PET Era? I…

7th Eurasian Hematology Oncology Summit

U. Vitolo

47 views
23:29

2020 Update on IO in R/R cHL: Is Long-Term Therapy w/ Nivo Feasible …

7th Eurasian Hematology Oncology Summit

T. Tuglular

138 views
15:27

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? …

7th Eurasian Hematology Oncology Summit

C. Gisselbrecht

200 views
21:20

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, a…

7th Eurasian Hematology Oncology Summit

C. Schiffer

695 views